medicine-news-1/life-beyond-cancer-womens-retreat-calls-for-applications-48335-3/;+health+history;+medical+history.html

Breaking Biology Technology:Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 2 Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 3 Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2 Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3 BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 2 BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 3 Oxford BioTherapeutics Appoints Michael Moore as Chairman 2 Oxford BioTherapeutics Appoints Michael Moore as Chairman 3 Oxford BioTherapeutics Appoints Michael Moore as Chairman 4

[0] Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum [0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease [0] BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes [0] Oxford BioTherapeutics Appoints Michael Moore as Chairman

Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2 Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 56 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 1 56 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 2 56 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3 Pelosi and Reid Invite President Obama to Address Congress 56085 1 Chindex International Announces September Investor Conferences Participation 56083 1 Chindex International Announces September Investor Conferences Participation 56083 2

[0] Boston Scientific Announces Pricing of $2 Billion of Senior Notes [0] Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy [0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer